Company / Gross Margin
Vanda Pharmaceuticals Inc. Gross Margin History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
25.6%
FY2019
5-year range
-
FY2016-FY2019
Trend
-3.4%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Margin has declined for 3 consecutive years, from 48.6% in FY2016 to 25.6% in FY2019.
Based on SEC 10-K filings.
25.6% in FY2019 with a 3-year CAGR of -23.0%.
Declined from 30.0% to 25.6% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- -23.0pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- Vanda Pharmaceuticals Inc.'s gross margin has declined for 3 consecutive years.
- In FY2019, gross margin decreased 3.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | 25.6% | -3.4% |
| FY2018 | 26.5% | -11.6% |
| FY2017 | 30.0% | -38.3% |
| FY2016 | 48.6% | -4.0% |
As of FY2019 · SEC 10-K · Updated Jun 28, 2026